Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.65 |
| ▸ | HPGD | P15428 | 11/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | GBA1 | P04062 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PLEC | Q15149 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926689 | 0.90 | HPGD (0.70) | KDM4EHPGDALDH1A1HSD17B10POLB | |
| SCHEMBL4203652 | 0.89 | HPGD (0.72) | KDM4EHPGDALDH1A1HSD17B10POLB | |
| SCHEMBL4212013 | 0.85 | KDM4E (0.76) | KDM4EHPGDALDH1A1HSD17B10POLB | |
| SCHEMBL14535837 | 0.82 | ALDH1A1 (0.57) | KDM4EHPGDALDH1A1HSD17B10HTT | |
| SCHEMBL4205006 | 0.81 | ALDH1A1 (0.76) | KDM4EHPGDALDH1A1HSD17B10HTT | |
| SCHEMBL4203423 | 0.80 | HPGD (0.60) | KDM4EHPGDALDH1A1HSD17B10CYP1A1 | |
| SCHEMBL1422926 | 0.79 | KDM4E (1.00) | KDM4EHPGDALDH1A1HSD17B10POLB | |
| SCHEMBL4200982 | 0.79 | POLB (0.66) | KDM4EHPGDALDH1A1HSD17B10POLB | |
| SCHEMBL21238857 | 0.78 | KDM4E (0.79) | KDM4EHPGDALDH1A1HSD17B10POLB | |
| SCHEMBL15992666 | 0.78 | MAPT (0.67) | KDM4EHPGDALDH1A1HSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | claimed |
| EP-3366688-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3366688-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2022-02-09 | — | — | EP | disclosed |
| US-10925874-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-23 | — | — | US | disclosed |
| US-10925874-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-23 | — | — | US | disclosed |
| US-20180263988-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2018-09-20 | — | — | US | disclosed |
| EP-3366688-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9974789-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-22 | — | — | US | disclosed |
| US-9974789-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-22 | — | — | US | disclosed |
| US-9974789-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160346284-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160346284-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160346284-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2016-12-01 | — | — | US | disclosed |
| US-9353117-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353117-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353117-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2012078855-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263988-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | GBA1, GAA, GBA3 | KDM4E 2174/4885HPGD 2444/4885ALDH1A1 2433/4885 |
| US-20160346284-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | GBA1, GAA, GBA3 | KDM4E 2174/4885HPGD 2444/4885ALDH1A1 2433/4885 |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | GBA1, GAA, GBA3 | KDM4E 2174/4885HPGD 2444/4885ALDH1A1 2433/4885 |
| US-10925874-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | GBA1, GAA, GBA3 | KDM4E 2174/4885HPGD 2444/4885ALDH1A1 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.